What is CRISPR Therapeutics AG (CRSP)?
CRISPR Therapeutics AG is a biotechnology company focused on developing gene-based medicines using CRISPR/Cas9 gene-editing technology. Founded in 2013 and headquartered in Switzerland, the company aims to create transformative therapies for serious diseases by precisely modifying DNA sequences within patients' cells. CRISPR Therapeutics collaborates with academic institutions and industry partners to advance its pipeline, which includes treatments for genetic disorders, cancers, and other conditions. The company's approach leverages the potential of CRISPR technology to address underlying genetic causes rather than symptoms. CRISPR Therapeutics is part of the broader field of genomic medicine and gene editing, contributing to advancements in biotechnology and personalized medicine. Its research and development efforts focus on both ex vivo and in vivo applications of gene editing.
CRISPR Therapeutics AG Stock Price Today: Live Overview
The price today is shaped by trading trends, with CRISPR Therapeutics AG at $49.04. Its price range for the session has been from $47.39 to $49.73, with a daily percentage movement of 0%.
FAQ: CRISPR Therapeutics AG (CRSP)
What is the current price of CRSP stock?
CRISPR Therapeutics AG's last traded price is $49.04.
Does CRSP pay dividends?
CRISPR Therapeutics AG does not pay dividends.
Does CRSP have a formal corporate presence or regional headquarters in the UAE?
CRISPR Therapeutics AG does not have an official office or subsidiary in the UAE and operates through partners and distributors.
What is CRSP best known for?
The company is most famous for its gene-editing technology using CRISPR-Cas9.
What assets are typically shown together with CRSP?
Commonly shown alongside CRSP: Inovio Pharmaceuticals, C4 Therapeutics, Inc., Universal Corp
Latest shares articles



